Paper Details

  1. Home
  2. Paper Details

Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes.

Author: NufferWesley, TrujilloJennifer M

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Albiglutide is a long-acting GLP-1 RA that lowers glycosylated hemoglobin (A1C) and reduces weight in patients with type 2 diabetes. It is the fourth GLP-1 RA approved in the United States, and it has a long half-life, allowing for once-weekly dosing. Albiglutide was shown to be superior to placebo, sitagliptin, and glimepiride and noninferior to insulin glargine and insulin lispro at reducing A1C. The most common side effects are upper-respiratory-tract infections, diarrhea, nausea, and injection-site reactions.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To review the pharmacology, pharmacokinetics, safety, and efficacy of albiglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA) in type 2 diabetes (T2D). DATA SOURCES: A MEDLINE search (1950-June 2014) was conducted using the keyword albiglutide. References were reviewed to iden...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1177/1060028014545807

データ提供：米国国立医学図書館（NLM）

Albiglutide: A New GLP-1 Receptor Agonist for Type 2 Diabetes

This study examines the pharmacological properties, pharmacokinetics, safety, and efficacy of albiglutide, a novel glucagon-like peptide-1 receptor agonist (GLP-1 RA) for treating type 2 diabetes (T2D). The study explores the mechanism of action, dosing regimen, and clinical trial findings related to albiglutide. The study's aim is to provide a comprehensive overview of this new therapeutic option for T2D patients.

Albiglutide: A Promising New Treatment Option for Type 2 Diabetes

The study highlights the potential of albiglutide as a promising new treatment option for T2D. The study's findings show that albiglutide, a long-acting GLP-1 RA, effectively lowers glycosylated hemoglobin (A1C) levels and reduces weight, improving metabolic control in T2D patients. The once-weekly dosing regimen makes albiglutide a convenient and potentially well-tolerated treatment option.

A New Oasis in the Desert of Diabetes Treatment

This study brings a breath of fresh air to the desert of diabetes treatment, offering a new and potentially effective option for T2D patients. It's like discovering a new spring of water in a parched land, providing hope and relief for those seeking better diabetes management. As a researcher, I am excited about the continued development of new medications for chronic diseases, and this study provides promising evidence for albiglutide's potential role in treating T2D.

Dr.Camel's Conclusion

This study explores the pharmacological properties, pharmacokinetics, safety, and efficacy of albiglutide, a novel GLP-1 RA for treating type 2 diabetes. The study's findings suggest that albiglutide is a promising new treatment option, offering effective glycemic control and weight reduction. It's a reminder that research and innovation are essential in advancing healthcare and improving the lives of those living with chronic diseases.

Date :
  1. Date Completed 2014-12-30
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

25136065

DOI: Digital Object Identifier

10.1177/1060028014545807

Related Literature

Article Analysis
・Side Effects of albiglutide injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.